Yes, ceftriaxone (Zeftrax) is an effective treatment option for leptospirosis
Ceftriaxone is equally effective as penicillin G for treating severe leptospirosis and offers practical advantages including once-daily dosing and broader antimicrobial coverage. The evidence supports its use for both severe and uncomplicated forms of this disease.
Evidence Supporting Ceftriaxone Use
The strongest clinical evidence comes from a prospective randomized trial comparing ceftriaxone (1g IV daily for 7 days) with penicillin G (1.5 million units IV every 6 hours for 7 days) in 173 patients with severe leptospirosis 1. Both treatments showed identical median fever resolution times of 3 days, with equal mortality rates (5 patients in each group) and no significant differences in organ dysfunction duration. This demonstrates therapeutic equivalence between the two antibiotics.
Additional research supports ceftriaxone's efficacy across disease severity. A retrospective study found that short-course ceftriaxone (3-6 days at 1-2g daily) achieved apyrexia within 2 days in all patients with both uncomplicated and severe leptospirosis, with no relapses observed 2. Another study of 22 patients with severe late leptospirosis treated with ceftriaxone 2g IV daily showed 21/22 recovered, with a superior adverse effect profile compared to penicillin regimens 3.
Practical Advantages of Ceftriaxone
The once-daily dosing schedule provides significant logistical benefits over penicillin's four-times-daily administration 1. This convenience facilitates outpatient parenteral antibiotic therapy (OPAT) for stable patients and improves medication adherence. Additionally, ceftriaxone's extended spectrum provides coverage against other potential bacterial pathogens that may be considered in the differential diagnosis 1.
Treatment Recommendations
For severe leptospirosis: Use ceftriaxone 1-2g IV once daily for 7 days 1, 3. Recent evidence suggests shorter courses (3-6 days) may suffice in patients responding rapidly to therapy, though this requires clinical judgment 2.
For uncomplicated cases: While the evidence primarily addresses severe disease, ceftriaxone appears effective for milder presentations as well 2.
Important Caveats
The FDA label for ceftriaxone does not specifically list leptospirosis as an approved indication 4, though it is approved for various bacterial infections including septicemia and meningitis caused by susceptible organisms. This represents off-label use supported by clinical trial evidence.
A 2024 Cochrane systematic review examining antibiotics for leptospirosis found very low-certainty evidence overall, noting that while antibiotics are commonly prescribed, definitive rigorous data supporting their use remains limited 5. However, this reflects the general paucity of high-quality trials in leptospirosis rather than evidence against antibiotic use. The available randomized trials, though limited in number, consistently show clinical benefit.
Monitor for ceftriaxone-specific adverse effects including gallbladder pseudolithiasis (particularly in pediatric patients), urolithiasis, and potential neurological reactions 4. Ensure adequate hydration during treatment.
Recent case reports continue to document successful outcomes with ceftriaxone-based regimens, including combination therapy with doxycycline in some instances 6, 7, though monotherapy with ceftriaxone appears adequate based on the randomized trial data.